Compare TransMedics Group Inc (TMDX) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Wendys Co — how do they compare? TransMedics Group Inc trades at $85.89 (market cap $3.06B), while Wendys Co trades at $7.55 (market cap $1.45B). The key difference: TransMedics Group Inc is far larger — about 2.1× Wendys Co's market cap, and Wendys Co pays a 3.68% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | WEN | |
|---|---|---|
Market Cap | $3.06B | $1.45B |
Sector | Technology | Consumer Cyclical |
52-Week High | $150.42 | $9.89 |
52-Week Low | $61.99 | $6.17 |
Enterprise Value | $3.46B | $5.18B |
Dividend Yield | — | 3.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Wendy's (WEN) trades at $7.61, down 5.23% on the day, reflecting bearish technical signals and negative sentiment following the collapse of Trian's potential take-private bid. The stock shows a low P/E of 11.54 and P/S of 0.66, indicating potential undervaluation, but faces declining net income margins and high debt levels. Recent earnings have consistently beaten expectations, yet U.S. traffic fell 12.5% in 2026, highlighting operational challenges under new CEO Bob Wright's turnaround plan.
The outlook is cautious; while valuation metrics appear attractive and analyst consensus targets $8.13, near-term risks from weak sales, high leverage, and failed M&A speculation outweigh opportunities. Investors should monitor execution of the five-point reset strategy for traffic recovery, but competitive pressures and inconsistent cash flow generation pose significant headwinds for shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
